Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

Axsome Therapeutics initiates phase II CONCERT study of AXS-12 in narcolepsy

Jan. 31, 2019

Genentech to discontinue phase III CREAD 1 & 2 studies of crenezumab in early sporadic Alzheimer's

Jan. 30, 2019

Phase IIb study of SB-623 for motor deficits associated with chronic ischemic stroke misses endpoint

Jan. 30, 2019

CAP-1002 demonstrates safety and efficacy in phase I/II HOPE-Duchenne study

Jan. 30, 2019

Discovery of multireceptor ligands as novel class of atypical antipsychotic drugs for schizophrenia

Jan. 30, 2019

Topline results from second phase III study of tanezumab in OA pain

Jan. 29, 2019

Small molecule targets the most common genetic cause of ALS

Jan. 29, 2019

Bacterial virulence factor contributes to brain damage in AD

Jan. 29, 2019

Neurogenic pain receptor identified

Jan. 29, 2019

Myelin can regenerate in MS but mostly doesn't

Jan. 28, 2019

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 27, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 26, 2026
Researchers identify innate immune barrier against melanoma
BioWorld
Australian researchers have identified a previously overlooked population of immune cells in the skin that physically restrain melanoma growth by engulfing live...
In the clinic for May 26, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: 858, A2 Biotherapeutics, AC Immune, Agendia, Agenus, Aktis, Ascentage,...
Cavalon Therapeutics and Northwestern patent new Cav1.3 blockers
BioWorld Science
Cavalon Therapeutics Inc. and Northwestern University have disclosed new voltage-gated calcium channel Cav1.3 blockers potentially useful for the treatment of...